Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating pembrolizumab (MK-3475) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma
• Localized Renal Pelvis and Ureter Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING